NICE has approved the first targeted treatment for chronic obstructive pulmonary disease (COPD), offering a new option to up ...

Dupilumab, a simple pre-filled pen that people inject themselves with every two weeks, is the first biologic that targets both the symptoms of COPD and an underlying cause of the disease. It brings ...

NICE has recommended dupilumab for adults with uncontrolled COPD and raised eosinophils, citing fewer exacerbations and ...

The National Institute for Health and Care Excellence (NICE), has published final draft guidance recommending dupilumab as a ...

Add Yahoo as a preferred source to see more of our stories on Google. A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of ...

NICE has estimated that around 40% of people with COPD have elevated blood levels of eosinophils and, if half the eligible ...

A biologic injection that reduces chronic obstructive pulmonary disease (COPD) flare-ups by around a third has been approved for use on the NHS in England and Wales. The National Institute for Health ...

Sanofi and Regeneron’s Dupixent (dupilumab) has received positive final draft guidance from the National Institute for Health ...

Add Yahoo as a preferred source to see more of our stories on Google. Woman’s World has affiliate partnerships. We receive compensation when you click on a link and make a purchase. Learn more! Sure, ...

(StatePoint) More than 11 million people in the United States are living with chronic obstructive pulmonary disease (COPD), including more than 3 million people with emphysema, a type of COPD. This ...